4basebio (LON:4BB) Releases Earnings Results

4basebio (LON:4BB) posted its earnings results on Monday. The company reported GBX (0.57) earnings per share (EPS) for the quarter, Digital Look Earnings reports.

4basebio Stock Down 0.5%

Shares of LON 4BB traded down GBX 2.70 on Tuesday, hitting GBX 559.80. The company had a trading volume of 239 shares, compared to its average volume of 1,353. 4basebio has a 12-month low of GBX 420 and a 12-month high of GBX 820. The business has a 50 day moving average of GBX 511.05 and a two-hundred day moving average of GBX 510.01. The company has a quick ratio of 3.52, a current ratio of 2.73 and a debt-to-equity ratio of 201.47. The firm has a market capitalization of £86.69 million, a P/E ratio of -5.14 and a beta of 1.09.

Analysts Set New Price Targets

Separately, Royal Bank Of Canada reduced their price target on shares of 4basebio from GBX 1,600 to GBX 1,400 and set an “outperform” rating on the stock in a research report on Monday, June 15th. One analyst has rated the stock with a Buy rating, According to data from MarketBeat.com, 4basebio has a consensus rating of “Buy” and a consensus price target of GBX 1,400.

About 4basebio

4basebio is a specialist life sciences group focused on supplying therapeutic synthetic DNA for gene therapies and gene-based vaccines and providing solutions for effective and safe delivery of DNA/RNA based products to patients.

Our focus is the development of high quality, GMP grade synthetic DNA as well as non-viral nanoparticles which can efficiently and safely deliver fully functional genes to patients. These products and technologies are also available for customers and partners with whom we endeavor to combine our capabilities and know-how to develop gene therapy solutions for clinical development and commercialisation.